Clinical trials: Hepatitis C Virus
Chronic Hepatitis C Virus Infection
Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection
Primary objective: To demonstrate non-inferiority in sustained virologic response (SVR, undetectable HCV RNA at Follow up week 12) between PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily and P1101 400 µg SC Q2W +…
- Trial name
- NCT04382937
- Testing
- P1101 + Ribavirin, PEG-Intron + Ribavirin
- Where
- 39 sites in China, South Korea and 1 more
- Volunteers
- 222 people
- Sponsor
- PharmaEssentia
Hepatitis C, Chronic
Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)
This is an open-label, randomized, comparative, multicenter, 48-week study designed to evaluate the efficacy and safety of combination treatment with pegylated interferon and ribavirin in adult subjects with a diagnosis of…
- Trial name
- NCT00202839
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Ribavirin
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Infection
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)
This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infections who…
- Trial name
- NCT02105701
- Testing
- Grazoprevir + Elbasvir, Ribavirin
- Volunteers
- 420 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
This study aims to evaluate whether an investigational monoclonal antibody, CT-011, is safe to give and if it helps patients with hepatitis C virus (HCV).
- Trial name
- NCT00962936
- Testing
- CT-011
- Where
- Israel
- Volunteers
- 13 people
- Sponsor
- CureTech Ltd
HCV
TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers
The purpose of this study is to evaluate the safety and tolerability of three different doses of TMC435350 compared to placebo in healthy Japanese males.
- Trial name
- NCT00752544
- Testing
- TMC435350
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C, Human Immunodeficiency Virus
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.
- Trial name
- NCT01667731
- Testing
- SOF, RBV
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 224 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
This randomized, open-label, multicenter study will evaluate the safety , efficacy and tolerability of the combination treatment RO5466731, RO5190591, ritonavir and Copegus (ribavirin) with or without RO5024048 in patients with…
- Trial name
- NCT01628094
- Testing
- RO5024048, RO5190591, RO5466731
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Infection
Study of a New MVA Vaccine for Hepatitis C Virus
The study is aimed at assessing the safety of AdCh3NSmut and the new candidate vaccine MVA-NSmut when administered sequentially, or alone, to healthy volunteers and patients with hepatitis C virus infection The study also aims at…
- Trial name
- NCT01296451
- Testing
- MVA-NSmut, AdCh3NSmut, AdCh3NSmut1
- Where
- 3 sites in United Kingdom
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- ReiThera Srl
Hepatitis C Virus
Japanese Bridging Study Conducted in the United States
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics following single oral and multiple oral doses BMS-791325 in healthy Japanese subjects.
- Trial name
- NCT00947245
- Testing
- BMS-791325
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)
This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered concomitantly with peg-interferon alfa-2b (Peg-IFN) and ribavirin (RBV) to treatment-naïve participants with…
- Trial name
- NCT01440595
- Testing
- Grazoprevir, Peginterferon alfa-2b (Peg-IFN), Ribavirin (RBV)
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
This trial will test the hypothesis that CF102 can safely and effectively suppress viral load in patients with chronic hepatitis C and high circulating levels of virus.
- Trial name
- NCT00790673
- Testing
- CF 102
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- Can-Fite BioPharma
Hepatitis C, Chronic
Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral infections. The purpose of this study is to evaluate the safety and antiviral effects of several different doses of PEG-rIL-29 (a man-made…
- Trial name
- EMERGE (NCT01001754)
- Testing
- PEG-rIL-29, Peginterferon alfa-2a, Ribavirin
- Where
- 79 sites in United States, Australia and 9 more
- Volunteers
- 600 people
- Sponsor
- ZymoGenetics
Chronic Hepatitis c
A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
The purpose of this study is to evaluate the pharmacokinetics and safety of ASC16 after 3-single dose(50mg、100mg、200mg) or fixed continuous dose(200mg) in healthy volunteers.
- Trial name
- NCT03430830
- Testing
- Ravidasvir 50mg, Ravidasvir 200mg
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Chronic Hepatitis C
A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
The purpose of the study is to determine the safety, pharmacokinetics and efficacy of orally administered VX-135 with ribavirin in treatment naive subjects with chronic hepatitis C infection.
- Trial name
- NCT01790100
- Testing
- VX-135, Ribavirin
- Where
- Moldova
- Volunteers
- 20 people
- Sponsor
- Alios Biopharma Inc.
Hepatitis C
A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)
The purpose of the study is to determine if combination therapy with daclatasvir (DCV) and sofosbuvir (SOF) for 8 weeks is safe and effective in patients who have never been treated previously without liver cirrhosis who are…
- Trial name
- NCT02556086
- Testing
- Daclatasvir, Sofosbuvir
- Where
- 17 sites in Canada, France
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.
This single arm study will evaluate the efficacy and safety of PEGASYS (180 micrograms sc weekly) plus ribavirin (1000-1200mg po daily) in treatment-naive Latino patients versus non-Latino Caucasian patients with chronic…
- Trial name
- NCT00107653
- Testing
- Ribavirin, Peginterferon alfa-2a
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 569 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients
The purpose of this study is to determine the change from baseline in HCV Ribonucleic acid (RNA) on Day 4 following three days of dosing with BMS-929075 in chronically genotype subtype 1a and 1b HCV infected subjects
- Trial name
- NCT01525212
- Testing
- BMS-929075
- Where
- 3 sites in Australia
- Sponsor
- Bristol-Myers Squibb
Chronic Genotype 1 Hepatitis C Virus Infection
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.
- Trial name
- NCT01247194
- Testing
- PPI-461
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 24 people
- Sponsor
- Presidio Pharmaceuticals, Inc.
Hepatitis C
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
The study is to investigate whether participants with hepatitis C virus (HCV) genotype 1 who have a history of non-response/relapse to peginterferon alfa-2a (PEG) and ribavirin (RBV) may benefit from treatment with triple therapy…
- Trial name
- NCT01183169
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Debiopharm International SA
Hepatitis C, Chronic, Hepatitis C
Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)
Enrolled patients will be recruited to two parallel groups during therapy for Hepatitis C. Patients in the first one will receive a patient assistance program, and patients in the second group will not.
- Trial name
- NCT00728494
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908), Patient Assistance Program
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.